Global IDO inhibitor Market Size By Type (Small Molecule, Cell Therapy), By Application (Cancer, Alzheimer's Disease), By Region, And Segment Forecasts, 2023 to 2032

The Global IDO Inhibitor Market was valued at USD 684.2 million in 2023 and is projected to surpass USD 1,453.9 million by 2031, growing at a CAGR of 9.8% during the forecast period from 2023 to 2031. Indoleamine 2,3-dioxygenase (IDO) inhibitors are gaining traction due to their potential to enhance cancer immunotherapy, particularly in combination with checkpoint inhibitors. The rising prevalence of cancer globally, increasing focus on personalized medicine, and an expanding pipeline of clinical trials are key drivers boosting market demand.

Drivers:

1. Rising Cancer Incidence:

The increasing global burden of cancer, particularly solid tumors, is a major driver for the IDO inhibitor market. As immune checkpoint therapies become more mainstream, IDO inhibitors are being investigated as adjunct therapies to improve efficacy.

2. Expansion of Clinical Trials:

Numerous IDO inhibitor candidates are undergoing clinical evaluation, often in combination with PD-1/PD-L1 inhibitors, spurring investment and innovation in the segment.

3. Growing Demand for Immuno-oncology:

As immuno-oncology emerges as a dominant strategy in cancer care, IDO inhibitors offer a promising pathway to overcome immune resistance and enhance treatment response.

Restraints:

1. Clinical Setbacks and Mixed Trial Results:

Several IDO inhibitors, including some previously high-profile candidates, have faced setbacks in late-stage trials, raising concerns over their standalone efficacy.

2. High Development Costs:

The extensive cost of drug development and the need for long-term clinical trials can limit entry and progress for small and mid-sized biotech firms.

Opportunity:

1. Combination Therapy Potential:

IDO inhibitors show great promise when used alongside immune checkpoint inhibitors, opening doors to more effective multi-targeted cancer therapies.

2. Unmet Needs in Rare and Refractory Cancers:

There is growing interest in IDO inhibitors for hard-to-treat cancers where traditional therapies have limited success.

3. Biomarker-Driven Approaches:

Incorporating biomarkers to identify responsive patient populations offers the potential to tailor therapies, increase success rates, and reduce unnecessary exposure.

Market by System Type Insights:

The market is segmented into Epacadostat, Navoximod, Linrodostat, and Others. Among these, Epacadostat held the largest market share in 2023 due to its widespread research adoption and advanced development stage. Despite mixed clinical outcomes, it remains a benchmark molecule in the IDO landscape.

The Linrodostat segment is expected to witness the highest growth rate, driven by promising early-phase trial data and strategic partnerships between biotech firms and large pharmaceutical players.

Market by End-use Insights:

By end use, the market is categorized into Hospitals, Cancer Research Centers, and Specialty Clinics. Hospitals accounted for the largest market share in 2023 due to the presence of advanced infrastructure and integration with ongoing clinical trials.

Cancer Research Centers are projected to grow rapidly as the demand for trial sites and precision oncology capabilities continues to rise globally.

Market by Regional Insights:

North America dominated the IDO inhibitor market in 2023, supported by advanced healthcare infrastructure, a high concentration of clinical trials, and strong investment in oncology research. The U.S. leads in both product approvals and research collaborations.

Asia-Pacific is anticipated to experience the fastest growth through 2031, attributed to rising cancer prevalence, improving healthcare infrastructure, and increased participation in international oncology trials, particularly in China and India.

Competitive Scenario:

Key players in the Global IDO Inhibitor Market include Incyte Corporation, NewLink Genetics, Bristol-Myers Squibb, Pfizer Inc., 4SC AG, Aurigene Discovery Technologies, iTeos Therapeutics, and Merck & Co., Inc. These companies are actively engaged in R&D, partnerships, and licensing agreements to strengthen their market presence.

Notable Developments:

In 2023, Incyte resumed early-stage trials for next-generation IDO inhibitors with improved selectivity.

Pfizer announced new combination trial results with its IDO inhibitor candidate and an anti-PD-L1 agent in 2024, showing positive immunogenicity signals.

In 2025, iTeos Therapeutics expanded its strategic collaboration with GSK to accelerate development of novel IDO-targeted compounds.

Scope of Work – Global IDO Inhibitor Market

Report Metric Details

Market Size (2023) USD 684.2 million

Projected Market Size (2031) USD 1,453.9 million

CAGR (2023–2031) 9.8%

Key Segments By System Type (Epacadostat, Navoximod, Linrodostat, Others); By End-use (Hospitals, Cancer Research Centers, Specialty Clinics)

Growth Drivers Rising cancer incidence, expansion of clinical trials, growing demand for immuno-oncology therapies

Opportunities Combination therapies, biomarker-driven treatments, expanding role in rare cancers

Key Market Developments:

April 2023: Incyte Corporation launched a new exploratory trial assessing a next-gen IDO inhibitor in combination with anti-CTLA-4 agents.

November 2023: Pfizer reported promising Phase 1b data combining its IDO inhibitor with pembrolizumab in advanced melanoma.

January 2024: iTeos Therapeutics entered a multi-million dollar agreement with GSK to co-develop dual-pathway immunotherapies involving IDO and TIGIT targets.

FAQs:

1) What is the current market size of the Global IDO Inhibitor Market?

The market was valued at USD 684.2 million in 2023.

2) What is the major growth driver of the Global IDO Inhibitor Market?

The primary growth driver is the rising demand for cancer immunotherapy and increasing clinical research activities.

3) Which is the largest region during the forecast period in the Global IDO Inhibitor Market?

North America holds the largest market share due to its advanced healthcare infrastructure and research intensity.

4) Which segment accounted for the largest market share in the Global IDO Inhibitor Market?

The Epacadostat segment led the market in 2023 due to its advanced clinical progress and trial presence.

5) Who are the key market players in the Global IDO Inhibitor Market?

Major players include Incyte Corporation, Bristol-Myers Squibb, Pfizer Inc., 4SC AG, and iTeos Therapeutics.